http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2006146801-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P41-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-37 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-4846 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-737 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-727 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-731 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-12 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-717 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-727 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-737 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 |
| filingDate | 2005-05-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2008-07-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2006146801-A |
| titleOfInvention | METHODS FOR TREATING COAGULOPATHIES USING SULPHATED POLYSACCHARIDES |
| abstract | 1. The use of non-anticoagulant sulfated polysaccharide (NASP) for the manufacture of a composition for the treatment of an individual in need of increased blood coagulation. 2. The use according to claim 1, wherein said NASP is selected from the group consisting of N-acetylheparin (NAH), N-acetyl-de-O-sulfated heparin (NA-de-o-SH), de-N-sulfated heparin (De -NSH), de-N-sulfated acetylated heparin (De-NSAH), iodic acid oxidized heparin (POH), chemically sulfated laminarine (CSL), chemically sulfated alginic acid (CSAA), chemically sulfated pectin (CSP), dextran sulfate (DXS ), oligosaccharides derived from heparin (HDO), pentosan polysulfate (PPS) and fucoidan. 3. The use of claim 2, wherein said NASP is NAH.4. The use of claim 2, wherein said NASP is PPS. 5. The use of claim 2, wherein said NASP is fucoidan. The use of claim 2, wherein said NASP is a fucoidan fragment that reduces clotting time in a dPT assay. The use according to any one of claims 1 to 6, wherein the NASP is administered at a dose of from about 0.01 mg / kg to about 100 mg / kg. The use according to claim 1, wherein the individual suffers from coagulopathy selected from the group consisting of chronic or acute coagulopathy, congenital bleeding disorders due to a deficiency of blood factor and acquired coagulation disorders. The use of claim 8, wherein the blood factor deficiency is a deficiency of one or more factors selected from the group consisting of factor V, factor VII, factor VIII, factor IX, factor XI, factor XII, factor XIII and von Willebrand factor. . The use according to claim 1, where |
| priorityDate | 2004-05-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 146.